SeptRx IPO is a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).
Results of InterSEPT trial will be used to apply for CE mark.
SeptRx CEO Scott Russell said they expect that InterSEPT trial results will position them for initial commercialization efforts in Europe.
